| 產(chǎn)品編號 | bs-23027R-Cy7 |
| 英文名稱(chēng) | Rabbit Anti-ACE2/Cy7 Conjugated antibody |
| 中文名稱(chēng) | Cy7標記的血管緊張素轉換酶2抗體 |
| 別 名 | ACE-2; ACE 2; Angiotensin converting enzyme 2; ACE related carboxypeptidase; ACEH; Angiotensin converting enzyme homolog; Angiotensin converting enzyme like protein; Angiotensin I Converting Enzyme (peptidyl dipeptidase A) 2; Angiotensin I converting enzyme 2; DKFZP434A014; EC 3.4.17; OTTHUMP00000022963; angiotensin-converting enzyme 2 precursor; ACE2_HUMAN; Angiotensin-converting enzyme 2; ACE-related carboxypeptidase; Angiotensin-converting enzyme homolog; Metalloprotease MPROT15; Processed angiotensin-converting enzyme 2. |
| 規格價(jià)格 | 100ul/2980元 購買(mǎi) 大包裝/詢(xún)價(jià) |
| 說(shuō) 明 書(shū) | 100ul |
| 研究領(lǐng)域 | 細胞生物 免疫學(xué) 信號轉導 |
| 抗體來(lái)源 | Rabbit |
| 克隆類(lèi)型 | Polyclonal |
| 交叉反應 | (predicted: Human, Mouse, Rat, ) |
| 產(chǎn)品應用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 87kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human ACE2 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: The protein encoded by this gene belongs to the angiotensin-converting enzyme family of dipeptidyl carboxydipeptidases and has considerable homology to human angiotensin 1 converting enzyme. This secreted protein catalyzes the cleavage of angiotensin I into angiotensin 1-9, and angiotensin II into the vasodilator angiotensin 1-7. The organ- and cell-specific expression of this gene suggests that it may play a role in the regulation of cardiovascular and renal function, as well as fertility. In addition, the encoded protein is a functional receptor for the spike glycoprotein of the human coronaviruses SARS and HCoV-NL63. [provided by RefSeq, Jul 2008]. Function: Carboxypeptidase which converts angiotensin I to angiotensin 1-9, a peptide of unknown function, and angiotensin II to angiotensin 1-7, a vasodilator. Also able to hydrolyze apelin-13 and dynorphin-13 with high efficiency. May be an important regulator of heart function. In case of human coronaviruses SARS and HCoV-NL63 infections, serve as functional receptor for the spike glycoprotein of both coronaviruses. Subunit: Interacts with ITGB1. Interacts with SARS-CoV and HCoV-NL63 spike glycoprotein. Subcellular Location: Processed angiotensin-converting enzyme 2: Secreted. Cell membrane; Single-pass type I membrane protein. Tissue Specificity: Expressed in endothelial cells from small and large arteries, and in arterial smooth muscle cells. Expressed in lung alveolar epithelial cells, enterocytes of the small intestine, Leydig cells and Sertoli cells (at protein level). Expressed in heart, kidney, testis, and gastrointestinal system. Post-translational modifications: N-glycosylation on Asn-90 may limit SARS infectivity. Proteolytic cleavage by ADAM17 generates a secreted form. Similarity: Belongs to the peptidase M2 family. Database links: Entrez Gene: 59272 Human Entrez Gene: 70008 Mouse Omim: 300335 Human SwissProt: Q9BYF1 Human SwissProt: Q8R0I0 Mouse Unigene: 178098 Human Unigene: 13451 Mouse Unigene: 129779 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 合成與降解（Synthesis and Degradation） ACE-2的分布范圍比較局限，ACE2主要在心臟、腎臟、睪丸中表達顯著(zhù)， 近來(lái)人們發(fā)現ACE2也分布在胃腸道、腦和肺臟中。 有關(guān)學(xué)者在研究心臟和腎臟中發(fā)現，ACE2在心肌缺血、腎功能衰竭、動(dòng)脈粥樣硬化和糖尿病并發(fā)癥中，ACE2對血管緊張素產(chǎn)生和降解過(guò)程中有一定的生理作用。 特別是對ACE2在具有生理活性的-活性肽產(chǎn)生過(guò)程中的作用更值得進(jìn)一步研究。 ACE2的發(fā)現為心血管病和腎臟病研究開(kāi)辟了新天地，并提供了新的治療靶點(diǎn)，可能導致未來(lái)心血管疾病治療策略的改變。 |
